NKTR-358

NKTR-358

NKTR-358 is a novel first-in-class regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions.

Research suggests that suboptimal levels of Treg cells, powerful inhibitory immune cells, and lack of Treg cell activity may underlie the development of autoimmune and inflammatory diseases, including lupus and psoriasis.

NKTR-358 works by targeting the IL-2 receptor complex and preferentially stimulating the proliferation of Treg cells without stimulating cytotoxic CD8+ T and CD4+ T cells, which drive autoimmune disease. Activation of Tregs suppresses disease-causing T cells and restores the body’s self-tolerance mechanisms.

Nektar entered a strategic collaboration with Eli Lilly and Company in 2017 to develop and commercialize NKTR-358. NKTR-358 is in clinical trials for the treatment of autoimmune and inflammatory diseases, including systemic lupus erythematosus (SLE), psoriasis, atopic dermatitis (AD) and ulcerative colitis (UC).
 

Pipeline


References

1.    The American Autoimmune Related Diseases Association. Autoimmune Statistics.

2.    Johns Hopkins University. Autoimmune Disease Research Center.

2021 Journal of Translational Autoimmunity

2020 ACR Convergence 2020 Meeting

2020 European E-Congress of Rheumatology (EULAR)

The Promise of Interleukin-2 Therapy Meeting, Paris, France

2019 EULAR European Congress of Rheumatology

2019 American College of Rheumatology Annual Meeting

2019 EULAR European Congress of Rheumatology

Treg Directed Therapy for Autoimmune Disorders Meeting – May 2018

Antigen-Specific Immune Tolerance Drug Development Summit – April 2018

American College of Rheumatology Annual Meeting, San Diego, CA

13th Annual World Congress on Inflammation